GeneDx announced on September 25, 2025, the introduction of GeneDx Infinity, its proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition. Infinity is touted as the largest rare disease dataset, serving as the foundation for GeneDx's ExomeDx and GenomeDx tests and accelerating diagnosis and drug discovery.
For over 25 years, GeneDx Infinity has been recognized as a gold-standard resource by genetics experts due to its unmatched scale, depth, and diversity. The dataset includes data from nearly one million exomes and genomes, paired with over seven million phenotypic datapoints, with 60% of exomes/genomes being parent/child trios.
This introduction leverages the AAP’s recent guidance recommending exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability. GeneDx, recognized as the #1 genomic testing brand among pediatric and genetic providers, aims to empower pediatricians to utilize Infinity's power to deliver more answers for their patients and fuel the future of genetic medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.